CSIMarket
 
Protokinetix Incorporated  (PKTX)
Other Ticker:  
 
 
Price: $0.0155 $0.00 3.333%
Day's High: $0.016 Week Perf: -17.55 %
Day's Low: $ 0.01 30 Day Perf: -2.52 %
Volume (M): 103 52 Wk High: $ 0.04
Volume (M$): $ 2 52 Wk Avg: $0.02
Open: $0.02 52 Wk Low: $0.01



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Protokinetix Incorporated
Protokinetix Incorporated is a biotechnology company based in Canada. The company specializes in developing and commercializing innovative therapeutics for the treatment of diseases. Protokinetix's key focus is on a proprietary technology known as AAGP' (Anti-Aging Glycoprotein), which has potential applications in various medical fields.

AAGP' is a peptide-based molecule that has shown promising results in preclinical studies, demonstrating its effectiveness in protecting cells from damage and improving their function. Protokinetix is currently conducting further research and development to explore the potential therapeutic applications of AAGP' in areas such as organ transplantation, cell and gene therapies, and regenerative medicine.

One of the notable advancements in Protokinetix's research is in the field of organ transplantation. The company has successfully demonstrated the ability of AAGP' to extend the viability and function of organs, potentially reducing the need for organ donors and improving outcomes for patients awaiting transplants.

Protokinetix Incorporated is committed to advancing its technology and bringing novel therapeutics to market. The company collaborates with academic institutions, research organizations, and industry partners to accelerate the development and commercialization of its products. Overall, Protokinetix's innovative approach and focus on AAGP' hold promise in the field of therapeutic interventions and improving patient outcomes.


   Company Address: 109 W Main St. Dalton 44618 OH
   Company Phone Number: 434-5041   Stock Exchange / Ticker: PKTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Protokinetix Incorporated

Protokinetix Incorporated Breaking Barriers in Pharma: Impressive Q3 Earnings Reflects Strong Growth



Protokinetix Incorporated, a major player in the pharmaceutical industry, recently released its earnings report for the third quarter of 2023. The results were not what shareholders expected as the company experienced a decline in operating income and increased losses compared to the previous year. However, there are indications of potential improvements in key areas, leading market participants to wonder if the company will bounce back in the near future. This article will delve into the details of Protokinetix's Q3 earnings report and analyze the implications for the company's future.
Operating Income Decline and Revenue Moderations
During the July to September period in 2023, Protokinetix's operating income decreased to $0.080391 million from $0.370042 million in the same quarter of 2022. This decline of 78.28% reflects a shrinking operating margin that dropped from 0% to 0% over the same period. Shareholders were not prepared for this moderation in revenue, which added to the concern surrounding the company's financial performance.

Protokinetix Incorporated

Protokinetix Incorporated Announces an Operating Profit of $0.115577 Million for Q2 2023, Amid Stiff Competition in the Major Pharmaceutical Preparations Sector

As a journalist covering the financial sector, I have been closely monitoring the earnings reports of various companies in the Major Pharmaceutical Preparations sector. Today, I am focusing on Protokinetix Incorporated (PKTX) and its recent financial results.
In the second quarter of 2023, PKTX reported an operating profit of $0.115577 million. While this may seem like a significant decline compared to the operating profit of $0.442153 million in the same period last year, it is important to consider the context of the current state of affairs for the company. PKTX experienced a shortfall of $-0.116 million in the second quarter of 2023, which is a concerning development considering the company was profitable in the same quarter of 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com